Diabetes Research PhD: How RNA-Splicing Variants May Drive Early-Onset Autoimmune Diabetes

Diabetes Research PhD: How RNA-Splicing Variants May Drive Early-Onset Autoimmune Diabetes

The project description lists an application deadline of 5 January 2027; it does not specify a closing time.

Quick Decision

The project starts from RNU4ATAC and RNU6ATAC variants associated with syndromic early-onset autoimmune diabetes, then asks how disruption of the widely used minor spliceosome could lead to selective beta-cell autoimmunity. The student would computationally rank roughly 700 U12-intron genes and test candidates in patient-derived material and B-cell, T-cell and/or beta-cell models. It suits applicants interested in functional genomics, genetics, immunology or diabetes; sample access and the prioritization path are key questions.

Research Problem and Doctoral Work

What Is Unsolved and Why It Matters

Most human introns are processed by the major spliceosome. A smaller class, U12-type introns, depends on the minor spliceosome and occurs in about 700 human genes. The project is built around the puzzle that inherited changes in RNU4ATAC or RNU6ATAC can disrupt this broadly used machinery yet lead to a specific autoimmune attack on insulin-producing pancreatic beta cells. The 2026 team paper describes early-onset cases with immune dysregulation and U12-intron retention, but the downstream genes and the cell types that make the disease specific remain unresolved. [S01, S20]

The advertised central question is: which incorrectly spliced U12-intron genes help drive immune attack on beta cells, and how? The motivation extends beyond a rare syndrome: the new finding may provide a tractable way to study pathways relevant to type 1 diabetes and autoimmune disease. That potential is a research rationale, not a promise of a biomarker, treatment or prevention strategy.

Work, Methods, and Potential Outputs

The work plan moves from computational prioritization to experimental follow-up:

1. Year 1: develop a framework to rank U12-intron genes using public single-cell expression atlases from immune and pancreatic cells, type 1 diabetes and autoimmunity genetics, existing patient RNA-sequencing and immune data, and annotations estimating sensitivity to minor-spliceosome failure.
2. Year 2: test intron retention in selected genes using patient-derived cells and an established droplet digital PCR assay; establish cell models.
3. Years 2–3: knock down or knock out three to five highest-priority genes, for example using CRISPR or siRNA, in B-cell, T-cell and/or beta-cell models. Readouts include flow cytometry, cytokine measurement and RNA-sequencing.
4. Final year: integrate the results, publish data and write the thesis.

The advertised readouts target immune activation, tolerance, antigen presentation, cell stress and survival. This is a genuine wet-lab/computational hybrid: skills taught include R/Python, single-cell and public genomic-data analysis, cell culture, CRISPR editing, digital PCR and flow cytometry. The expected research output is an empirically supported set of U12-intron genes and a better account of their effects on immune and beta-cell behaviour. The number and type of cell models, control design, rescue experiments, sample sizes and exact criteria for selecting genes are not specified. Ask how those choices will be made before committing to a proposed mechanistic storyline. [S01]

Recent Important Publications

These papers show the scientific context and the team’s recent activity. The 2026 RNU study is the direct starting point; the others are related evidence, not a substitute for the work advertised.

• Johnson et al., American Journal of Human Genetics (2026): reports biallelic RNU6ATAC variants in seven individuals from four families and RNU4ATAC variants in 12 unrelated individuals with early-onset diabetes. Twelve of 19 had additional immune dysregulation, and half of those tested were islet-autoantibody positive. RNA-sequencing found U12-intron retention, while transcriptomic and immune analyses pointed to impaired B-cell development and maturation. This establishes the disease association and suggests an immune mechanism; it does not identify which downstream U12 genes cause beta-cell-directed attack. PubMed lists a linked August 2026 erratum, so consult the corrected article and erratum when using detailed figures or counts. [S20]
• Luckett et al., Diabetes (2025): compared 62 people with monogenic autoimmune diabetes with 180 controls with non-autoimmune neonatal diabetes. Higher type 1 diabetes genetic risk, driven in part by the DR3-DQ2 HLA haplotype, contributed to the clinical presentation. It supports considering polygenic context alongside rare disease variants, while the studentship’s planned gene-ranking framework will need to test its own evidence weights. [S21]
• Bonfield et al., Diabetes (2026): identified five new cases with biallelic IL2RA variants and reviewed reported cases; early-onset diabetes occurred in 14 of 22 people with biallelic IL2RA variants. This adjacent Exeter-led study illustrates how immune-tolerance genes can link immune dysregulation and beta-cell autoimmunity. It is not a minor-spliceosome result. [S22]
• Russ-Silsby et al., Molecular Metabolism (2025): reported complete PAX4 loss as a cause of transient neonatal diabetes. This is a separate beta-cell genetics problem, but demonstrates the wider team’s use of rare-variant cohorts to connect genotype with human diabetes phenotypes. [S23]

Field Outlook and Potential Research Angles

Functional genomics is increasingly aimed at moving from variant or gene discovery to mechanism in defined cell types, using single-cell data, transcriptomics, perturbation and genome editing. That agenda is also explicit in the national training programme. A 2026 independent lupus study reported U12-type splicing abnormalities in low-density granulocytes and associations with disease activity and autoantibodies. It broadens interest in minor-spliceosome biology across immune disease, but remains a distinct disease context and its associations do not prove that splicing defects cause lupus or that the same mechanism operates in diabetes. [S04, S25]

The advertised work could produce useful comparisons between (a) genes highly expressed in immune versus beta cells, (b) genes implicated by type 1 diabetes/autoimmunity genetics, and (c) genes whose introns appear most sensitive to minor-spliceosome failure. A practical research angle is whether a transparent, reproducible ranking can be calibrated against patient-cell intron retention before perturbation. Another is whether the perturbation readouts separate direct beta-cell stress from altered immune activation or tolerance. These are analytical possibilities, not extra promised aims. Feasibility depends on sample access, cell-model availability, perturbation efficiency and how the team handles a very large candidate set.

School, Programme and Field Context

The University of Exeter is the primary institution named for this project, based in Clinical and Biomedical Sciences. Exeter’s research-degree page lists the MPhil/PhD Clinical and Biomedical Sciences route, multiple Exeter locations and full-time or part-time study modes; this award is specifically described as a four-year FGx-DLA studentship, with September 2027 entry. The national award connects six universities and offers shared cohort training and often inter-institutional supervision. Those network activities do not establish a joint degree: Exeter is the listed host, and the formal registration and supervisor arrangement should be confirmed in the written offer. [S01, S03, S04, S06]

Exeter reports QS World University Rankings 2027 overall rank 136 and Times Higher Education World University Rankings 2026 overall rank =170. In REF 2021, its Clinical Medicine unit (UoA 1) was 45% four-star and 48% three-star, with 7% two-star activity. These measures indicate institutional and broad clinical-research context, not a rating of this specific project or supervisor. The department highlights clinical medicine, diabetes and genomics research; the NIHR Exeter Biomedical Research Centre describes work spanning genetic discovery, genomic diagnosis and patient-oriented diabetes research. [S07–S13]

Supervisor and Lab Assessment

Supervisor Research Directions

The official project document names Matthew Johnson as lead supervisor and gives m.johnson@exeter.ac.uk for project-specific enquiries. Exeter and the diabetes research team list him within the Clinical and Biomedical Sciences/monogenic-diabetes community. The recent papers above show activity in monogenic diabetes, autoimmune diabetes and human immune mechanisms. The formal role of additional supervisors, day-to-day contact frequency and access to collaborators are not described. Do not assume every coauthor or listed group member will supervise this studentship. [S01, S10, S11, S20–S24]

Lab, Resources, and Collaboration Environment

The project document states that the student will join Exeter’s diabetes research team and describes access to unique cohorts of people with early-onset and monogenic diabetes, a molecular-biology laboratory with established minor-spliceosome assays, high-performance computing and genomics facilities, flow cytometry, cell culture and gene-editing facilities. It also notes links to NHS clinical and diagnostic genetics services, international collaborators and Exeter’s Coding for Reproducible Research training. The BRC’s diabetes and genetics themes add a visible translational context. These are advertised resources; the exact patient-derived material, data permissions, cell models, instrument access and collaborator commitments for this project still need confirmation. [S01, S12–S14]

Funding, Application, and Living Cost

The project is listed under Exeter’s MRC Functional Genomics Doctoral Landscape Award. The 2027 round is listed as running from 26 October 2026 through Tuesday 5 January 2027. The award is four years full time, with part-time study available at programme level. Funding covers UK tuition fees and a doctoral stipend matching the UK Research Council minimum, currently £21,805 per year for 2026/27 and updated annually. Up to £5,000 per year is available for research training and support. UKRI’s table also lists £5,238 as the 2026/27 fee level. The final award letter should specify the 2027/28 rate and the project’s support allocation. [S02, S03, S05]

The national programme page says Exeter is among the institutions where international students do not need to supplement UKRI funding for the international-fee difference. This directly addresses the fee top-up question for this project under current programme guidance. Confirm that the written offer identifies the same FGx-DLA route and covers the full tuition charge; annual fee and stipend rates may be updated. [S04]

The application has two required stages: submit Exeter’s online programme application, then complete the FGx-DLA Applicant Questionnaire using the applicant ID. The questionnaire allows up to three project preferences, but only one application per person is accepted. The stated minimum is a 2:1 honours degree or international equivalent in a relevant area; accepted areas include genetics, molecular biology, biomedical or human biology, biochemistry, medicine, healthcare, bioinformatics, computer science or statistics. The typical English requirement is IELTS 7.0 overall with no component below 6.5, or equivalent, with evidence by the deadline. Applicants provide two academic referees who are not in the proposed supervisory team. If shortlisted, referees must send letters from institutional email accounts seven days before interview; the applicant must arrange this. Documents must be in English, with certified translations of academic qualifications where relevant. The questionnaire asks about motivation, a significant achievement, research experience and any use of generative AI in preparing the application. The public material does not state whether an additional project proposal is required. [S03, S04]

Exeter estimates basic living expenses for one student at £1,300–£2,000 per month, based on local spending in April 2026. Dividing the current £21,805 stipend by 12 gives about £1,817 per month: inside that broad range, but about £183 below its upper estimate before initial setup costs, travel, dependants or visa expenses. This is a planning comparison, not a personal budget. The separate Student visa financial-evidence requirement for study outside London is £1,171 per month for up to nine months, subject to exemptions and rule changes; it is not a forecast of actual expenses. [S05, S15, S16]

Career Paths and Market Context

Experience in genomic analysis, genetics, perturbation studies and quantitative cell biology may transfer to academic research, biotechnology and translational research. NHS clinical bioinformatics in genomics is a related route combining biology, computing, statistics and medical data, but it has separate clinical-scientist training and registration requirements; this PhD alone does not confer that status. Skills England and the Office for Life Sciences estimate 66,000 additional jobs (44%) across priority life-sciences occupations from 2025 to 2035, while emphasizing uncertainty. This is a broad sector estimate, not a forecast for this project or its graduates. No project-specific placement rate or employer commitment is advertised, and these pathways do not guarantee employment. (Skills England/Office for Life Sciences life-sciences assessment, Life Sciences Sector Plan, NHS Health Careers: clinical bioinformatics (genomics))

Applicant Fit and Preparation

Required Background and Skills

The programme’s formal academic requirement is a 2:1 honours degree or international equivalent in a relevant discipline. The advertised project welcomes biological, biomedical, computational, mathematical and data-science backgrounds and says full training will be provided in unfamiliar areas. No prior R/Python, single-cell, CRISPR, digital-PCR or flow-cytometry experience is stated as a formal prerequisite. [S01, S03]

Preferred Experience and Suggested Preparation

Useful evidence could include a research project showing careful analysis, reproducible code, handling of genomic or single-cell data, human genetics, immunology, cell biology, or laboratory controls. Applicants do not need to present every skill in the workflow. It will help to explain how existing strengths transfer to the project’s other half: for example, a computational candidate’s readiness to learn wet-lab work, or a laboratory candidate’s approach to learning R/Python and interpreting public genomic datasets.

Before applying, read the 2026 RNU4ATAC/RNU6ATAC study and prepare to discuss candidate prioritization, cell-type evidence and validation logic. Avoid proposing extra experiments as though they are already funded. Ask whether a short project proposal is expected and how preferences are assessed if listing more than one project. [S01, S03, S20]

Next Actions and Questions to Verify

Before Applying

1. Contact Matthew Johnson to confirm the full supervisory team, project-specific proposal expectations and whether Exeter currently has the described patient-derived samples and cell models available.
2. Ask how access to patient data/cells is governed and whether sample numbers are sufficient for the proposed comparisons.
3. Confirm that the application will be evaluated under the FGx-DLA route, and submit both the online application and questionnaire by 5 January 2027. Arrange two eligible academic referees early.
4. If applying internationally, retain the programme page’s Exeter no-top-up statement and ask how full international tuition coverage will appear on the formal offer.

At Interview

1. Ask how the candidate-ranking framework will combine expression, genetic evidence and predicted intron sensitivity, and what benchmark will be used before selecting targets.
2. Clarify how three to five knockdown/knockout targets, control groups and potential rescue experiments are feasible within the four-year plan.
3. Ask which cell types and functional readouts are committed, how project progress is adjusted if one model is unavailable, and what portion of the work is computational versus laboratory-based.
4. Ask how routine supervision, inter-institutional collaboration and national cohort training are organized.

Before Accepting an Offer

1. Check the formal degree registration and Exeter location, the full tuition-fee statement, stipend for the 2027/28 start year, four-year duration and any part-time terms.
2. Confirm what the up-to-£5,000 annual training/support amount covers for this project, and whether there are any project costs that the student must meet.
3. Review the corrected 2026 RNU4ATAC/RNU6ATAC paper and linked erratum if the project’s proposed starting model relies on specific reported results.

Evidence and Sources

Project and Programme

• S01 Official project description: Uncovering the mechanism of minor spliceosome autoimmune diabetes
• S02 Exeter studentship award 6025
• S03 Medical Research Council Functional Genomics Doctoral Landscape Award
• S04 Postgraduate research – UK Human Functional Genomics Initiative

School, Supervisor and Research Environment

• S06 Clinical and Biomedical Sciences PhD and Research Degrees
• S07 Department of Clinical and Biomedical Sciences
• S08 University of Exeter league tables and rankings
• S09 University of Exeter REF 2021 results
• S10 Diabetes researchers at the University of Exeter
• S11 Diabetes Genes research team
• S12 Genetics and Genomics – NIHR Exeter Biomedical Research Centre
• S13 Diabetes research – NIHR Exeter Biomedical Research Centre
• S14 NIHR Exeter Clinical Research Facility laboratory facilities

Funding, Costs and Career Context

• S05 Guidance for training grant holders – UKRI
• S15 Budgeting for international students – University of Exeter
• S16 Student visa: money you need – GOV.UK
• S17 Sector Skills Needs Assessment – Life sciences
• S18 Life Sciences Sector Plan
• S19 Clinical bioinformatics (genomics) – NHS Health Careers

Research Papers

• S20 Johnson et al. (2026), RNU6ATAC and RNU4ATAC cause syndromic monogenic autoimmune diabetes
• S21 Luckett et al. (2025), Type 1 diabetes genetic risk in monogenic autoimmune diabetes
• S22 Bonfield et al. (2026), Biallelic pathogenic variants in IL2RA cause neonatal-onset monogenic autoimmune diabetes
• S23 Russ-Silsby et al. (2025), Complete loss of PAX4 causes transient neonatal diabetes in humans
• S24 Johnson et al. (2024), Human inherited PD-L1 deficiency and PD-1 deficiency
• S25 Dysregulation of U12-Type Splicing in Lupus Neutrophils (2026)